Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009 American Academy of Ophthalmology Annual Meeting in San Francisco, California, USA

Lumenis Introduces Advanced Retinal Laser Delivery Technology at the 2009
American Academy of Ophthalmology Annual Meeting in San Francisco, California,
USA

SANTA CLARA, Calif., Oct. 27 /PRNewswire/ -- Lumenis Ltd. a global developer,
manufacturer and marketer of laser, light-based and radiofrequency devices for
ophthalmic, surgical and aesthetic applications, announced today that it
introduced a breakthrough ophthalmic laser delivery technology on October 24th
at the American Academy of Ophthalmology (AAO) Annual Meeting in San
Francisco, California, USA.

Dov Ofer, Lumenis' President and Chief Executive Officer stated: "Lumenis is
proud to be yet again at the forefront of ophthalmic laser technology with the
introduction of InSight®, a fully integrated, advanced retinal laser delivery
technology and slit lamp bio-microscope. This achievement continues Lumenis'
40-year history of ophthalmic laser innovation. In 1970 we were the very first
company to introduce a laser in this field; since then, we have followed with
a series of additional sight-preserving milestones, including the first laser
photocoagulator, laser indirect ophthalmoscope, multicolor photocoagulator,
photodynamic (PDT) laser, the revolutionary Selective Laser Trabeculoplasty
(SLT) system, and solid state multicolor laser."

"At this year's AAO Meeting, we continue this long-standing tradition as we
proudly showcase the newest addition to our existing and already robust
product portfolio of ophthalmic lasers and delivery devices. Our InSight
represents the latest in retina visualization and laser delivery technology,
and it successfully addresses some of the well-known challenges in ophthalmic
laser delivery devices, namely, clear visualization of the retina and precise
laser delivery to the target tissue," said Dov Ofer.

"We are very excited to significantly expand our capabilities in the Retina
segment with the introduction of InSight," said Mr. Lloyd Diamond, Vice
President & General Manager of Lumenis Vision, the ophthalmic business unit of
Lumenis. "The InSight was designed to truly elevate performance and precision
to new levels - allowing general ophthalmologists and retina specialists to
customize each treatment and exercise complete control throughout the laser
procedure. This ability is achieved through our unique and patented co-linear
optical design, which projects both illumination and laser beam through the
same pathway. Furthermore, the CoLin mechanism is controlled directly through
InSight's integrated joystick, which also features our patented AcuGuide(TM)
technology for fine movement and beam manipulation. With this technology, our
customers can command complete control of the laser procedure literally with
their fingertip."

"The InSight significantly facilitates laser delivery to the retina. Whether
you are performing pan-retinal photocoagulation or a macular focal or grid
laser treatment, the InSight provides you with complete control throughout the
procedure, making the procedure easier for the treating physician," stated Dr.
Pazit Pianka MD, an Ophthalmologist and Medical Director of Lumenis Vision.

In addition to incorporating the most advanced laser delivery and optics
technology, ergonomic factors play a key role in the product design, as we
recognize the tremendous benefit these represent to ophthalmologists and their
patients. "The InSight is a valuable addition to the Lumenis ophthalmic
product portfolio, further enhancing and protecting our global leadership
position in the markets we serve," concluded Mr. Diamond.

About the American Academy of Ophthalmology and 2009 Annual Meeting

The American Academy of Ophthalmology is the largest national membership
association of ophthalmologists, medical doctors who provide comprehensive eye
care, including medical, surgical and optical care. More than 90 percent of
practicing U.S. ophthalmologists are Academy members, and the Academy has more
than 7,000 international members. The Academy's 113th Annual Meeting was held
from October 24 to 27 in San Francisco, CA. The 2009 Annual Meeting program
highlighted how technology advances are improving patient care. For more
information about the AAO and Annual Meeting, log on to http://www.aao.org.

About Lumenis
Lumenis, the world's largest medical laser company, is a global developer,
manufacturer and distributor of laser, light-based and radiofrequency devices
for surgical, aesthetic and ophthalmic applications, with more than 800
employees worldwide. Lumenis has over 250 patents, over 75 FDA clearances, an
installed base of over 80,000 systems and presence in over 100 countries.
Lumenis endeavors to bring the finest state of the art technology products to
the market, fulfilling the highest standards of excellence, quality and
reliability. Consequently we are able to deliver premium value and service to
our customers. Lumenis' name is derived from Latin meaning "Light of Life",
highlighting the light which is the basis of our technologies used to enhance
life. For more information about Lumenis and its products, please go to:
www.lumenis.com.

Lumenis, its logo, VersaPulse , SlimLine and Slimline GI are trademarks or
registered trademarks of the Lumenis Group of Companies.

Certain statements and information in this press release may be deemed to be
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements may include,
but are not limited to, statements relating to our objectives, plans and
strategies, statements that contain projections of results of operations or of
financial condition and all statements (other than statements of historical
facts) that address activities, events or developments that we intend, expect,
project, believe or anticipate will or may occur in the future.
Forward-looking statements are often characterized by the use of
forward-looking terminology such as "may," "will," "expect," "anticipate,"
"estimate," "continue," "believe," "should," "intend," "project" or other
similar words, but are not the only way these statements are identified. We
have based these forward-looking statements on assumptions and assessments
made by our management in light of their experience and their perception of
historical trends, current conditions, expected future developments and other
factors they believe to be appropriate. Any forward-looking statements in this
press release are made as of the date hereof, and we undertake no obligation
to publicly update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise. Forward-looking
statements are not guarantees of future performance and are subject to risks
and uncertainties. Important factors that could cause actual results,
developments and business decisions to differ materially from those
anticipated in these forward-looking statements may be found in our most
recent Annual Report on Form 20-F, including the section therein entitled
"Risk Factors", as well in our reports on Form 6-K, filed with the Securities
and Exchange Commission.

SOURCE Lumenis Ltd.

Michelle Maydan, Director of Corporate Communications, +1-866-569-0597, or
+972-4-959-9004, mmaydan@lumenis.com